```html

Juvenile Stevens‑Johnson Syndrome (SJS) – A Complete Guide for Patients and Caregivers

Overview

Stevens‑Johnson syndrome (SJS) is a rare, life‑threatening hypersensitivity reaction that involves the skin and mucous membranes. When it occurs in children and adolescents, it is often referred to as “juvenile SJS.” The condition represents a severe end of a spectrum that also includes toxic epidermal necrolysis (TEN). While SJS can affect anyone, children under 18 account for roughly 15–20 % of all reported cases worldwide.<sup>[1]</sup>

Key points:

• Incidence: 1–6 cases per million children per year in the United States; slightly higher in regions with extensive drug use or viral outbreaks.<sup>[2]</sup>
• Gender: Slight female predominance (about 55 %).
• Age group: Most cases occur in children 6–16 years, but infants can be affected.

Symptoms

Symptoms appear abruptly, usually within 1–3 weeks after exposure to a trigger (drug, infection, etc.). Early recognition is crucial because the disease can progress rapidly.

General skin manifestations

• Fever & malaise: Often the first sign, temperature >38 °C.
• Prodromal flu‑like symptoms: Headache, sore throat, cough.
• Macules & papules: Flat or raised red spots that may spread.
• Target lesions: Classic “bullseye” lesions with a dusky center, erythematous rim, and pale peripheral ring.
• Blistering and epidermal detachment: Affects <10 % of body surface area (BSA) in SJS (vs. >30 % in TEN).
• Positive Nikolsky sign: Gentle pressure causes the top layer of skin to peel.

Mucosal involvement (present in >90 % of cases)

• Oral cavity: Painful erosions, hemorrhagic crusts, difficulty swallowing.
• Eyes: Conjunctivitis, eyelid edema, pseudomembranes, risk of symblepharon (adhesions).
• Genitalia: Vaginal or penile erosions, painful urination.
• Respiratory tract: Hoarseness, cough, possible airway ulceration.
• Gastrointestinal: Rarely, ulcerations in the esophagus or colon.

Systemic signs

• Dehydration from fluid loss through skin lesions.
• Electrolyte abnormalities (e.g., hyponatremia).
• Acute kidney injury secondary to hypovolemia or drug toxicity.

Causes and Risk Factors

Juvenile SJS is an immune‑mediated reaction, most often triggered by medications or infections. The exact pathogenesis involves cytotoxic T‑cell activation and massive keratinocyte apoptosis.

Common triggers

• Medications (≈70 % of cases):
  • Antibiotics – especially sulfonamides, penicillins, and quinolones.
  • Antiepileptics – carbamazepine, lamotrigine, phenytoin.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs) – especially oxicam derivatives.
  • Allopurinol and other urate‑lowering drugs.
• Infections (≈30 %): Mycoplasma pneumoniae, herpes simplex virus (HSV), varicella‑zoster, HIV, and recent respiratory infections.
• Vaccinations: Extremely rare; reported after measles‑mumps‑rubella (MMR) and influenza vaccines.

Risk factors

• Genetic predisposition – HLA‑B*1502 in Asian populations increases carbamazepine risk (up to 100‑fold).<sup>[3]</sup>
• Previous SJS/TEN episode – recurrence risk ~20 %.
• Concurrent infections – viral illnesses can amplify drug hypersensitivity.
• Immunocompromised state – HIV, transplant patients.

Diagnosis

There is no single laboratory test for SJS; diagnosis is clinical, supported by investigations to rule out mimickers and assess severity.

Clinical assessment

• Detailed history of recent drug exposure (last 1–3 weeks) and infections.
• Physical examination focusing on skin BSA involvement and mucosal sites.
• SCORTEN score – a validated severity index for TEN but also used for SJS to predict mortality (age, heart rate, cancer, BSA >10 %, serum urea, glucose, bicarbonate).<sup>[4]</sup>

Laboratory tests

• Complete blood count (CBC) – may show leukocytosis or eosinophilia.
• Metabolic panel – monitor electrolytes, renal and hepatic function.
• Inflammatory markers – CRP, ESR (nonspecific).
• Serology/PCR for suspected infections (e.g., Mycoplasma IgM, HSV PCR).
• Drug-specific lymphocyte transformation test (LT test) – limited availability, useful for research.

Skin biopsy

Performed when diagnosis is uncertain. Histology shows full‑thickness epidermal necrosis, subepidermal blister formation, and a sparse lymphocytic infiltrate – features characteristic of SJS/TEN.

Treatment Options

Management of juvenile SJS requires a multidisciplinary approach (dermatology, ophthalmology, pediatrics, burn unit, infectious disease). Prompt withdrawal of the offending agent and supportive care are the cornerstones.

Immediate measures

1. Stop the trigger: Discontinue any suspected medication immediately.
2. Hospital admission: Most children need care in a burn unit or intensive care setting.
3. Fluid & electrolytes: Replace losses using isotonic crystalloids; aim for 3–5 mL/kg/h in the first 24 h.

Pharmacologic therapies

• Corticosteroids: High‑dose intravenous methylprednisolone (1–2 mg/kg/day) is controversial but may be considered within the first 48 h in centers with experience. Monitor for infection.
• Intravenous immunoglobulin (IVIG): Dose 2 g/kg divided over 2–3 days. Some studies suggest reduced mortality when given early, especially in children.<sup>[5]</sup>
• Cyclosporine: 3 mg/kg/day has shown benefit in adult SJS/TEN; pediatric data are emerging.
• TNF‑α inhibitors (e.g., etanercept): Small pediatric case series report faster skin healing and fewer ocular complications.
• Antibiotics: Only for proven bacterial infection; prophylactic antibiotics are not recommended.
• Pain control: IV opioids, acetaminophen, or NSAIDs (once renal function is stable).

Supportive care

• Wound care – non‑adherent dressings, daily assessment, and antiseptic solutions (e.g., diluted chlorhexidine).
• Ophthalmology – lubricating eye drops, topical antibiotics, and early referral for potential amniotic membrane transplantation.
• Nutrition – high‑protein, high‑calorie enteral feeding; consider nasogastric tube if oral intake is impossible.
• Psychological support – anxiety and post‑traumatic stress are common after severe illness.

Living with Juvenile Stevens‑Johnson Syndrome

Even after acute recovery, many children face long‑term sequelae. The following strategies help families navigate daily life:

• Skin care: Use fragrance‑free moisturizers twice daily; avoid tight clothing that can irritate healed areas.
• Ocular health: Continue lubricating drops for at least 6 months; attend regular ophthalmology visits to detect late scarring.
• Genital care: Gentle cleansing, barrier creams, and local estrogen ointment (if post‑pubertal) for vaginal adhesions.
• Vaccination updates: Discuss timing with the pediatrician; most vaccines are safe once the skin has fully healed.
• School re‑integration: Provide a written plan for medication safety (avoid high‑risk drugs), and arrange for a school nurse to monitor hydration.
• Genetic counseling: For families with HLA‑B*1502 or other risk alleles, consider testing before prescribing high‑risk medications.

Prevention

Because most cases are drug‑induced, avoidance strategies are the most effective.

1. Medication review: Before starting any new medication, especially antibiotics, antiepileptics, or NSAIDs, discuss the child’s history of drug reactions.
2. Pharmacogenomic testing: In high‑risk ethnic groups (e.g., Southeast Asian), test for HLA‑B*1502 before using carbamazepine or oxcarbazepine.<sup>[3]</sup>
3. Prompt treatment of infections: Early antibiotics for bacterial infections and antiviral therapy for HSV can reduce the chance of infection‑related SJS.
4. Educate caregivers: Provide lists of “danger drugs” and ensure all healthcare providers have access to a medication allergy card.
5. Skin protection: Avoid unnecessary sun exposure during the healing phase; use broad‑spectrum sunscreen (SPF 30+) once re‑epithelialization is complete.

Complications

Complications can be immediate or develop months to years later.

Acute complications

• Sepsis – due to loss of skin barrier.
• Acute respiratory distress syndrome (ARDS) – from airway involvement.
• Acute kidney injury – from hypovolemia or drug toxicity.
• Severe dehydration and electrolyte imbalance.

Long‑term sequelae

• Ocular: Chronic dry eye, symblepharon, cataracts, glaucoma, or vision loss (up to 30 % of severe cases).<sup>[6]</sup>
• Cutaneous: Hyper‑ or hypopigmentation, scarring, milia, and skin fragility.
• Genitourinary: Vaginal stenosis or penile curvature.
• Psychological: Depression, anxiety, post‑traumatic stress disorder (PTSD).
• Growth & development: Nutritional deficits during illness can affect height and weight gain.

When to Seek Emergency Care

References

1. Mayo Clinic. Stevens‑Johnson syndrome and toxic epidermal necrolysis. Updated 2023.
2. CDC. Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis (TENS) Surveillance. 2022.
3. FDA. HLA‑B*1502 Testing for Carbamazepine Use in Asian Populations. 2020.
4. SCORTEN Study Group. Validation of a Severity‑of‑Illness Score for Toxic Epidermal Necrolysis. J Invest Dermatol. 2001.
5. Rzany B, et al. Intravenous immunoglobulin for Stevens‑Johnson syndrome and toxic epidermal necrolysis: systematic review. Dermatology. 2021.
6. World Health Organization. Ocular Complications of Stevens‑Johnson Syndrome and TEN. 2022.

```